z-logo
open-access-imgOpen Access
Cell-Based Phenotypic Drug Screening Identifies Luteolin as Candidate Therapeutic for Nephropathic Cystinosis
Author(s) -
Ester De Leo,
Mohamed A. Elmonem,
Sante Princiero Berlingerio,
Marine Berquez,
Beatrice Paola Festa,
Roberto Raso,
Francesco Bellomo,
Tobias Starborg,
Manoe J. Janssen,
Zeinab Abbaszadeh,
Sara Cairoli,
Bianca Maria Goffredo,
Rosalinde Masereeuw,
Olivier Devuyst,
Martin Lowe,
Elena Levtchenko,
Alessandro Luciani,
Francesco Emma,
Laura Rita Rega
Publication year - 2020
Publication title -
journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.451
H-Index - 279
eISSN - 1533-3450
pISSN - 1046-6673
DOI - 10.1681/asn.2019090956
Subject(s) - cystinosis , cysteamine , fanconi syndrome , cystine , lysosomal storage disease , medicine , chemistry , endocrinology , cancer research , kidney , biochemistry , cysteine , disease , enzyme
Mutations in the gene that encodes the lysosomal cystine transporter cystinosin cause the lysosomal storage disease cystinosis. Defective cystine transport leads to intralysosomal accumulation and crystallization of cystine. The most severe phenotype, nephropathic cystinosis, manifests during the first months of life, as renal Fanconi syndrome. The cystine-depleting agent cysteamine significantly delays symptoms, but it cannot prevent progression to ESKD and does not treat Fanconi syndrome. This suggests the involvement of pathways in nephropathic cystinosis that are unrelated to lysosomal cystine accumulation. Recent data indicate that one such potential pathway, lysosome-mediated degradation of autophagy cargoes, is compromised in cystinosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom